Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”

James D. Douketis

doi:10.1160/TH12-04-0236

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(02): 210-212
DOI: 10.1160/TH12-04-0236

Pro/Contra Article

Schattauer GmbH

Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”

James D. Douketis

¹Department of Medicine, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

› Author Affiliations

Abstract

Full Text

References

References
1 Douketis JD, Spyropoulos AC, Spencer FA. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis (9^th Edition). Chest 2012; 141 (Suppl. 02) e326S-350S.
2 O’Donnell MJ, Kearon C, Johnson J. et al. Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146: 184-187.
3 Douketis JD, Woods K, Foster GA. et al. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94: 528-531.
4 Pengo V, Cucchini U, Denas G. et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119: 2920-2927.
5 Malato A, Saccullo G, Lo Coco L. et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost 2010; 08: 107-113.
6 Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 2005; 03: 2823-2825.
7 Dunn AS, Spyropoulos A, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 05: 2211-2218.
8 National Institutes of Health Clinical Center. A safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin. NCT00432796. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007
9 National Institutes of Health Clinical Center. Effectiveness of bridging anticoagulation for surgery. NCT00786474. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2008
10 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
11 Garcia DA, Regan S, Henault LE. et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-69.
12 Daniels PR, McBane RD, Litin SC. et al. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res 2009; 124: 300-305.
13 Wysokinski WE, McBane RD, Daniels PR. et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008; 83: 639-645.
14 Douketis JD, Berger PB, Dunn AS. et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8^th Edition). Chest 2008; 133: 299S-339S.
15 Jaffer AK, Ahmed M, Brotman DJ. et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005; 20: 11-16.
16 Tafur AJ, McBane R II, Wysokinski WE. et al. Predictors of major bleeding in periprocedural anti-coagulation management. J Thromb Haemost 2012; 10: 261-267.
17 Yudin J, Siegal D, Lim W. et al. Perioperative heparin bridging in patients receiving oral anticoagulation: meta-analysis of bleeding and thromboembolic rates. Blood 2011; 118: 545.
18 Kaatz S, Douketis JD, Zhou H. et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 08: 884-890.
19 Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92: 479-485.
20 López Y, Páramo JA, Valentí JR, Pardo F, Montes R, Rocha E. Hemostatic markers in surgery: a different fibrinolytic activity may be of pathophysiological significance in orthopedic versus abdominal surgery. Int J Clin Lab Res 1997; 27: 233-237.
21 Kosir MA, Schmittinger L, Barno-Winarski L. et al. Prospective double-arm study of fibrinolysis in surgical patients. J Surg Res 1998; 74: 96-101.
22 POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839-1847.
23 Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
24 NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.